Michael Stecher

1.0k total citations
28 papers, 643 citations indexed

About

Michael Stecher is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Michael Stecher has authored 28 papers receiving a total of 643 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 7 papers in Immunology. Recurrent topics in Michael Stecher's work include Colorectal Cancer Treatments and Studies (15 papers), Gastric Cancer Management and Outcomes (10 papers) and HER2/EGFR in Cancer Research (7 papers). Michael Stecher is often cited by papers focused on Colorectal Cancer Treatments and Studies (15 papers), Gastric Cancer Management and Outcomes (10 papers) and HER2/EGFR in Cancer Research (7 papers). Michael Stecher collaborates with scholars based in United States, France and Belgium. Michael Stecher's co-authors include John Simard, Prasant Mohanty, Razelle Kurzrock, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Aung Naing, Jennifer J. Wheler, Gerald S. Falchook, Siqing Fu and Filip Jankú and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Michael Stecher

27 papers receiving 637 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Stecher United States 11 253 247 200 115 102 28 643
Kayhan Ertürk Türkiye 15 136 0.5× 211 0.9× 329 1.6× 57 0.5× 54 0.5× 81 577
Elisa Pasini Canada 14 124 0.5× 195 0.8× 274 1.4× 108 0.9× 124 1.2× 40 791
Remco van Dijk Netherlands 11 61 0.2× 146 0.6× 145 0.7× 152 1.3× 135 1.3× 19 564
Anna Ragaz United States 9 199 0.8× 102 0.4× 137 0.7× 50 0.4× 202 2.0× 20 613
Kimon Tzannis Greece 11 54 0.2× 179 0.7× 99 0.5× 115 1.0× 43 0.4× 40 471
Claudia Wegscheid Germany 14 641 2.5× 91 0.4× 135 0.7× 68 0.6× 21 0.2× 20 869
Stine Roug Denmark 11 151 0.6× 88 0.4× 93 0.5× 189 1.6× 22 0.2× 17 476
Jan-Hendrik Riedel Germany 9 500 2.0× 71 0.3× 87 0.4× 83 0.7× 27 0.3× 13 661
Shohei Egami Japan 10 213 0.8× 121 0.5× 60 0.3× 115 1.0× 29 0.3× 27 591
S. Petrasch Germany 17 187 0.7× 81 0.3× 194 1.0× 125 1.1× 24 0.2× 36 642

Countries citing papers authored by Michael Stecher

Since Specialization
Citations

This map shows the geographic impact of Michael Stecher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Stecher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Stecher more than expected).

Fields of papers citing papers by Michael Stecher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Stecher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Stecher. The network helps show where Michael Stecher may publish in the future.

Co-authorship network of co-authors of Michael Stecher

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Stecher. A scholar is included among the top collaborators of Michael Stecher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Stecher. Michael Stecher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Singh, Harshabad, Lisa Bloudek, Ling‐I Hsu, et al.. (2023). Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer. JNCI Cancer Spectrum. 8(1). 9 indexed citations
2.
Strickler, John H., Ling‐I Hsu, Phoebe Wright, et al.. (2023). Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study. Journal of the National Comprehensive Cancer Network. 21(8). 805–812.e1. 5 indexed citations
3.
Strickler, John H., Andrea Cercek, Kimmie Ng, et al.. (2023). HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.. Journal of Clinical Oncology. 41(16_suppl). 3528–3528. 5 indexed citations
4.
Strickler, John H., Andrea Cercek, Kimmie Ng, et al.. (2023). 551O Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in MOUNTAINEER. Annals of Oncology. 34. S411–S412. 2 indexed citations
5.
6.
Strickler, John H., Andrea Cercek, Salvatore Siena, et al.. (2022). LBA27 Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC. Annals of Oncology. 33. S1394–S1394. 5 indexed citations
7.
Siena, Salvatore, Élena Elez, Marc Peeters, et al.. (2021). PD-1 MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress). Annals of Oncology. 32. S199–S199. 3 indexed citations
8.
9.
Strickler, John H., Kimmie Ng, Andrea Cercek, et al.. (2020). 523TiP MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer. Annals of Oncology. 31. S460–S461. 1 indexed citations
10.
11.
Hickish, Tamas, Thierry André, Lucjan Wyrwicz, et al.. (2017). MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology. 18(2). 192–201. 121 indexed citations
12.
Kanni, Theodora, Themistoklis Spyridopoulos, Aikaterini Pistiki, et al.. (2017). MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study. Journal of Investigative Dermatology. 138(4). 795–801. 83 indexed citations
13.
Hickish, Tamas, Lucjan Wyrwicz, Tomasz Sarosiek, et al.. (2016). O-027 A pivotal phase 3 trial of MABp1 in advanced colorectal cancer. Annals of Oncology. 27. ii128–ii128. 3 indexed citations
14.
Rupp, Mark E., Michael Stecher, John E. McKinnon, Norma Jung, & Toan Huynh. (2016). Pharmacokinetics of a Novel Monoclonal Antibody Targeting Staphylococcal Protein A in Patients Hospitalized With S. aureus Bacteremia. Open Forum Infectious Diseases. 3(suppl_1). 1 indexed citations
15.
Goel, Sanjay, Lucjan Wyrwicz, Andrew L. Coveler, et al.. (2016). Phase III double-blinded, placebo-controlled study of MABp1 for improving survival in metastatic colorectal cancer.. Journal of Clinical Oncology. 34(4_suppl). TPS784–TPS784. 2 indexed citations
16.
Sayed, Hosam El, Richard A. Kerensky, Michael Stecher, Prasant Mohanty, & Mark G. Davies. (2015). A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous revascularization. Journal of Vascular Surgery. 63(1). 133–141.e1. 39 indexed citations
17.
Hong, David S., Filip Jankú, Aung Naing, et al.. (2015). Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Investigational New Drugs. 33(3). 621–631. 55 indexed citations
18.
Carrasco, Daniel, Michael Stecher, Gigi Lefebvre, Alan Logan, & Ronald L. Moy. (2015). An Open Label, Phase 2 Study of MABp1 Monotherapy for the Treatment of Acne Vulgaris and Psychiatric Comorbidity.. PubMed. 14(6). 560–4. 11 indexed citations
19.
Hong, David S., David Hui, Éduardo Bruera, et al.. (2014). MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. The Lancet Oncology. 15(6). 656–666. 162 indexed citations
20.
Rundell, William & Michael Stecher. (1979). The Nonpositivity of Solutions to Pseudoparabolic Equations. Proceedings of the American Mathematical Society. 75(2). 251–251. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kayhan Ertürk Breakdown of academic impact, for papers by Elisa Pasini Breakdown of academic impact, for papers by Remco van Dijk Breakdown of academic impact, for papers by Anna Ragaz Breakdown of academic impact, for papers by Kimon Tzannis Breakdown of academic impact, for papers by Claudia Wegscheid Breakdown of academic impact, for papers by Stine Roug Breakdown of academic impact, for papers by Jan-Hendrik Riedel Breakdown of academic impact, for papers by Shohei Egami Breakdown of academic impact, for papers by S. Petrasch
Rankless by CCL
2026